Location: Room K1

In this scene setter session, join leading industry advisors Citeline and IQVIA, as they discuss key challenges facing decision makers in research-driven biopharma companies. From R&D through to market access and launch excellence, in key disease areas such as rare diseases, the conversation will touch on the fast-changing dynamics across the entire biopharmaceutical value chain. This data driven fireside chat, filled with relevant case studies, is highly educational and sets the scene for the in-depth panel discussions to follow throughout BIO-Europe.

Location: Room K1

As the biopharma industry experiences unprecedented scientific advancements, along with shifting priorities of both pharmaceutical and biotech companies, this session explores whether it is time for a rethink of how strategic synergies are identified and leveraged in biopharma deals, and how they are combined and nurtured once the deal is done. Gain insights into emerging trends, the importance of aligning scientific innovation with commercial potential, actionable strategies to rethink the approach to M&A in a rapidly evolving market, and how to foster an environment of mutual growth and innovation after a deal is signed and, in the years to come.

Location: Room K1

In an era of unprecedented scientific advancements, the life sciences sector is ripe with opportunities for groundbreaking discoveries. However, translating these discoveries into marketready solutions requires a robust and resilient venture ecosystem. This panel session will bring together corporate and financial venture capitalists to discuss strategies for fortifying the European venture landscape, ensuring it is well-equipped to support the next generation of life science breakthroughs.

Location: Room K1

Should mentorship be a two-way street between CEOs and biotech investors? This panel aims to uncover how CEOs and investors can significantly benefit from exchanging mentor roles and insights to drive collective success for biotech companies. Learn more about the dynamics of mutual mentorship, understand risks and rewards from engaging in reverse learning, and listen to investors and C-level professionals share real life experiences.

Location: Room K2

Location: Room K2

Location: Room K11

Through their EMEA Advance Biotech Grant Program, Merck recognize standout emerging biotech companies and helps them navigate their path to commercialization. Delivered as a dynamic competition, five selected biotech companies will have the opportunity to pitch their breakthroughs to Merck's Grant representatives and the overall BIO-Europe audience.

Location: Exhibit Stage

Explore the complexities of gender equality in the Nordic region. While the Nordics have made significant strides in comparison to other regions, taking a closer look reveals that challenges remain. Join this session to discover the challenges that still exist and understand the importance of the need for continuous advocacy, despite the significant progress made.

Targeting three key groups: the seasoned female leader, men and the up-and-coming generation of female leaders, the session celebrates the contributions in setting the ceiling for future generations to walk on, why and how men should get involved, inclusively, and the current experience of today’s generation of female leaders.

Location: Room K11

From the get-go, start-up and pre-clinical stage biopharmaceutical companies rightfully prioritize the scientific foundation of their invention, then swiftly transitioning towards Clinical Development. The priority is often reserved for securing fast-track, accelerated development pathways and expediting entry into first-in-human studies. Undoubtedly, Clinical Development stands as the key in the drug Information Classification: General development journey, commanding utmost attention: it is the highest risk, highest value creation, highest cost, most challenging, and highly regulated and monitored by Regulators Agencies. However, this pursuit of clinical milestones frequently results in the oversight of Chemistry, Manufacturing, and Controls (CMC) Development. Such neglect stems from underestimating the scope, complexity, timelines, cost, and impact of CMC Development - a prerequisite and indispensable precursor to any Toxicology and Clinical Development. This presentation will cover how to fully integrate CMC Development into the product development lifecycle and how pursuing excellence in CMC development will allow start-up and pre-clinical stage biopharmaceutical companies to realize substantial value.